Access to Eloctate

On February 24, the CHS Board of Directors formally objected to the recent CBS decision to restrict access to Eloctate for children under 12 and called on the CBS to reverse its decision.

LEARN MORE

Access to Hemlibra

On February 18, the CHS responded to the CBS medical/scientific review and the CADTH economic analysis of Hemlibra (emicizumab) for patients with hemophilia A with and without inhibitors.

LEARN MORE

Hemophilia Today

Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.

LEARN MORE

Research

Are there inequities in access to care amongst certain groups of patients with bleeding disorders?
St. Michael’s Hospital is conducting a study on access to care, in collaboration with the Canadian Hemophilia Society. People 18 years and older with a bleeding disorder are being asked to consider participating.

LEARN MORE

CHS 2017 Annual Report

The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.

Read the report here.

Q&A about RFPs

We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.

Learn more

Recombinant factor concentrate charts

Please check out our updated charts listing the recombinant factor concentrates and their description.

Click here for the rFVIII chart

Click here for the rFIX chart

REACH US AT

1-800-668-2686

chs@hemophilia.ca

WE’RE HERE TO HELP.

CONTACT US

FIND A TREATMENT CENTRE NEAR YOU

SEARCH